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vast number of cellular processes (Bashir & Pagano, 2003; Hershko
& Ciechanover, 1998; Pickart, 2004) and deregulation of the UPS is
implicated in the pathogenesis of various diseases including cancer.
The substrate speciﬁcity of the ubiquitin system is achieved
through the use of a large number of E3 ubiquitin ligases that
selectively bind to and mediate the covalent attachment of a single
or chains of ubiquitin to substrates (Weissman, 2001). Poly‐
ubiquitylated substrates are recognized and degraded by the
proteasome. However, ubiquitin conjugation also has non‐
proteolytic roles in processes such as transcription (Chen &
Sun, 2009). The SCF (Skp1/Cul1/F‐box) multi‐subunit E3s
generally consist of the core subunits Skp1, Cul1 and the ring‐
ﬁnger protein Roc1 bound to a variable F‐box protein that dictates
substrate speciﬁcity (Bai et al, 1996; Cenciarelli et al, 1999; Skowyra
et al, 1997). Up to 70 different genes encoding F‐box proteins have
been identiﬁed in the human genome, but only a handful have
been characterized (Skaar et al, 2009), some with potent functions
as either tumour suppressors or tumour promoters (Frescas &
Pagano, 2008; Nakayama & Nakayama, 2006).
TheMYConcoprotein/transcription factor controls the expression
of up to 15% of the cellular transcriptome, and serves as a master
regulator of various biological functions (Adhikary & Eilers, 2005;
Larsson & Henriksson, 2010; Meyer & Penn, 2008). Together with
MAX, MYC binds to speciﬁc E‐box DNA recognition sequences
(CACGTG or similar sequences) at target genes and activates
transcription by recruiting multiple co‐activator complexes (Adhik-
ary & Eilers, 2005; Larsson & Henriksson, 2010; Meyer & Penn,
2008). Recent ﬁndings suggest thatMYC functions as an ampliﬁer of
expression from active or poised promoters by stimulation of
transcription elongation (Bouchard et al, 2004; Eberhardy &
Farnham, 2001; Guccione et al, 2006; Lin et al, 2012; Nie et al,
2012; Rahl et al, 2010). Overexpression of MYC induces oncogenic
transformation, and its deregulation inmultiple humanmalignancies
contributes to a large fraction of human cancers (Adhikary &
Eilers, 2005; Larsson & Henriksson, 2010; Meyer & Penn, 2008).
Here, we identify a hitherto uncharacterized F‐box gene,
FBXO28, encoding a cell cycle regulated protein with a critical
function in tumour cell proliferation. FBXO28 assembles an
SCFFBXO28 ubiquitin ligase whose activity is regulated during
progression through the cell cycle by cyclin‐dependent kinase 1/2
(CDK1/2)‐mediated phosphorylation. Phosphorylation of FBXO28
at serine 344 enables the SCFFBXO28 ubiquitin ligase to target the
oncoprotein MYC for non‐proteolytic ubiquitylation, thereby
fueling MYC‐driven transcription, proliferation and tumouri-
genesis. Importantly, we ﬁnd that FBXO28 expression and
phosphorylation to be strongly associated with poor prognosis
and worse overall survival (OS) in human breast cancer.RESULTS
The F‐box protein FBXO28 regulates tumour cell proliferation
To identify novel F‐box proteins required for tumour cell
proliferation, we performed a high‐throughput short interferings, Ltd on behalf of EMBO.targets the complete set of human F‐box genes. Cells from
different types of tumour cell lines were reverse transfected with
pools of F‐box speciﬁc siRNAs and the effects on proliferation
were assessed by EdU incorporation using the Cell Spot
MicroArray method (CSMA) (Rantala et al, 2011). This screen
identiﬁed several previously uncharacterized F‐box genes, the
depletion of which caused clear and consistent inhibitory effects
on proliferation (Fig 1A).
To validate these results, we applied the CSMA method using
a library of siRNAs (Qiagen Druggable genome v1.0) comprising
a total of 6135 genes, including 53 F‐box genes, in KPL4 breast
cancer cells using Ki‐67 as a proliferation marker (Fig 1B).
Interestingly, of the top 200 siRNAs that most potently reduced
Ki‐67 expression, nine were F‐box genes (Supporting Informa-
tion Table S1). Enrichment analysis of functional categories
using DAVID (Dennis et al, 2003) conﬁrmed the striking
enrichment of the F‐box gene family (p ¼ 3.0E7). In particular,
FBXO28 depletion led to a potent inhibitory effect on prolifera-
tion in both siRNA screens (Fig 1A and Supporting Information
Table S1) and was therefore selected for further in depth
analysis.
Flow cytometry and time‐lapse microscopy analyses con-
ﬁrmed that depletion of FBXO28 resulted in a progressive loss of
proliferation, evident from around 36–48 h of siRNA silencing in
several different tumour cell lines (Fig 1C and D; Supporting
Information Fig S1A–C). Knockdown of FBXO28 also decreased
the proliferation of normal human IMR90 cells and human
diploid ﬁbroblasts (HDFs), although to a lesser extent than the
tumour cell lines (Fig 1C). This was not due to induced cell death
(unpublished data), suggesting a cytostatic mode of action.
Together these results support an important function for FBXO28
in the regulation of cellular proliferation.
FBXO28 is phosphorylated by CDK1/2 and is part of an SCF
ubiquitin ligase complex
The human FBXO28 gene encodes a highly conserved nuclear
protein (Fig 2A; Supporting Information Fig S2B) of 368 amino
acids (aa) that contains an F‐box motif in its N‐terminus (aa 67–
94, Supporting Information Fig S2A), but lacks other discernable
domains. Tryptic phosphopeptide analysis of immunopuriﬁed
FBXO28 revealed a peptide with a high conﬁdence score for
phosphoserine modiﬁcation at amino acid 344 (LREVME-
SAVGNSSGSGQNEEpSPR) that conforms to a conserved CDK
consensus phosphorylation motif (S/T)PX(K/R) at the FBXO28
C‐terminus (Supporting Information Fig S2C). Using antibodies
speciﬁcally recognizing FBXO28 phosphorylated on S344
(Supporting Information Fig S2D–F) we found that pS344‐
FBXO28 is also mainly localized to the nucleus (Fig 2A;
Supporting Information Fig S2D and F). Analysis of FBXO28
levels during progression through the cell cycle in HeLa cells
showed that FBXO28 phosphorylation is minimal in G1 phase
and high during S‐G2/M phase (Fig 2B). The total FBXO28 level
also declined in G1 with a slight delay and subsequently
increased later in the cell cycle, coinciding with FBXO28
phosphorylation (Fig 2B). Notably, the FBXO28 phosphorylation
pattern resembled the expression of the S and G2 cyclins, cyclinEMBO Mol Med (2013) 5, 1067–1086
Figure 1. FBXO28 regulates tumour cell proliferation.
A. Hierarchical partitioning around medoids (PAM) clustering of the z-score results of the F-box RNAi screen in the indicated cell lines. The genes are ranked
according to EdU incorporation, with more EdU (red) at the top and less EdU (blue) at the bottom. The p-values (Student’s t-test) for siFBXO28 compared to
control siRNA were p ¼ 0.00729 in MCF7, p ¼ 0.00366 in KPL4, p ¼ 0.0207 in A549 and p ¼ 0.0200 in HCT116 (n ¼ 4 replica per group and cell line).
B. Global siRNA screen in KPL4 breast cancer cells, using Ki-67 as a proliferation marker. Scatter plot distribution of z-score results, where red dots represent
siRNAs targeting F-box genes.
C. EdU incorporation monitored by flow cytometry following siRNA depletion of FBXO28 for 48 h. Upper panels: representative FACS analysis in U2OS
osteosarcoma cells. Lower panel: Percentage of EdU positive cells upon FBXO28 silencing in the indicated cell lines. HCT116 and U2OS were pulsed with EdU
for 20 min, while IMR90 and HDFs were pulsed for 4 h before analysis. Bars indicate standard error of the mean (SEM) from three independent experiments in
HCT116, U2OS and IMR90 and two experiments in HDF. p-values (shown above the bars) were determined by the Student’s t test compared to siScramble for
each cell line. p-values not calculated for HDF.
D. Growth curves of U2OS cells transfected with two different FBXO28 siRNAs compared with scrambled control siRNAs. The data represent the mean  SEM of
three cell counts for each time point and condition. Note that cells were exposed to siRNAs for 48 h before re-plating in equal numbers, followed by cell
counting at days 3, 4 and 5. No significant difference in cell number was evident after 48 h siRNA transfection (unpublished data).
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Diana Cepeda et al.A2 and cyclin B1 (Fig 2B), raising the question whether FBXO28
could be phosphorylated by the associated CDKs. Indeed,
in vitro kinase assays using puriﬁed recombinant cyclin/CDK
complexes, revealed that both cyclin A‐CDK2 and cyclin B‐
CDK1, but not cyclin E‐CDK2, efﬁciently phosphorylated
in vitro‐translated wild‐type (WT) FBXO28, but not a mutant
protein where S344 was replaced with alanine (S344A) (Fig 2C).
Consistently, overexpression of dominant‐negative (DN) CDK1
or CDK2 mutants reduced phosphorylation at S344 (Fig 2D).
Interestingly, treatment of cells with the CDK1/2 inhibitor
roscovitine not only reduced FBXO28 phosphorylation, but also
had a profound effect on the total abundance of FBXO28 protein
(Fig 2E). Coincubation with the proteasome inhibitor MG‐132
almost fully restored FBXO28 protein levels (Fig 2E), suggesting
that CDK‐mediated phosphorylation inﬂuenced the turnover of
FBXO28. This was veriﬁed by cycloheximide (CHX) chase
analysis, demonstrating more rapid degradation of the S344A‐
FBXO28 mutant as compared to WT‐FBXO28 or a phosphomi-
metic S344E mutant (Fig 2F). Deletion of the F‐box domain
(which connects F‐box proteins to the E3 ligase complex via
Skp1) in FBXO28 (DF‐FBXO28) did not impede phosphorylation
at S344 but stabilized the protein (Supporting Information Fig
S2G and H), indicating that FBXO28 might regulate its own
turnover through auto‐ubiquitylation. In order to test whether
FBXO28 forms an SCFFBXO28 complex in cells, we performed
coimmunoprecipitation experiments with WT‐FBXO28 or DF‐
FBXO28 and epitope‐tagged SCF subunits. As shown in Fig 2G,
WT‐FBXO28 efﬁciently copuriﬁed with the core ligase, whereas
DF‐FBXO28 failed to do so, demonstrating that FBXO28 is part of
an SCF ubiquitin ligase capable of interacting with the ubiquitin
machinery.
FBXO28 regulates expression of MYC target genes
Since proliferation and transcriptional control are tightly linked
processes regulated by ubiquitin ligases, we investigated the
consequences of FBXO28 depletion on global gene expression by
microarray analysis (Operon Biotechnologies). Strikingly, deple-
tion of FBXO28 in HCT116 cells resulted in considerable changes
in gene expression already after 16 h of siRNA transfection, andFigure 2. FBXO28 is a nuclear protein phosphorylated by CDK1/2 that assem
A. Immunostaining for endogenous FBXO28 protein in IME cells with FBXO28 (u
counterstained with Hoechst (blue). Scale bars, 10 mm.
B. Cell cycle profile of FBXO28 expression. HeLa cells were released by mitotic sh
from whole cell lysates were used for immunoblotting (IB) analysis with the ind
cell cycle was documented by flow cytometry (unpublished data). AS, asynchr
C. In vitro translated FBXO28 (WT or S344A) protein was subjected to in vitro kinas
was performed with the indicated antibodies. Total cell lysate (TCL) from U2O
D. Protein extracts from HEK293 cells transfected with the indicated HA-tagged ex
with the indicated antibodies. WT, wild-type; DN, dominant-negative.
E. Lysates of Cos7 cells transfected with GST-FBXO28 or empty vector (EV) and tre
analysed by IB analysis. Upper panel: Exogenous (GST-FBXO28) and endogenou
Phosphorylated FBXO28 level was analysed by IB using pS344-FBXO28 antibo
F. Cycloheximide (CHX) chase analysis of WT andmutant forms of FBXO28 (S344A
as depicted.
G. FBXO28 is part of an SCF complex. HEK293 cells were cotransfected with exp
FBXO28, DF-FBXO28 or EV and FBXO28 was purified on GST-beads. Bound pr
EMBO Mol Med (2013) 5, 1067–1086  2the majority of the differentially expressed genes were down-
regulated (88 and 71% at 16 and 36 h, respectively (GEO
Accession no; GSE36112). The gene expression changes occured
well before any signs of loss of proliferation (Supporting
Information Fig S1A) and are therefore not likely a result of
the proliferation arrest per se. Gene ontology (GO) analysis
demonstrated that the most differentially expressed transcripts
were genes involved in rRNA processing, ribosome biogenesis,
cell cycle and metabolism (Fig 3A). This expression proﬁle is
highly reminiscent of transcriptional processes regulated by the
oncoprotein/transcription factor MYC (Adhikary & Eilers, 2005;
Eilers & Eisenman, 2008; Larsson & Henriksson, 2010; Meyer &
Penn, 2008). Gene Set Enrichment Analysis (GSEA) (Subrama-
nian et al, 2005) also suggested that MYC‐activated genes were
downregulated in response to FBXO28 depletion. Analyses using
a deﬁned gene set of known MYC targets (Fredlund et al, 2008)
revealed their signiﬁcant enrichment among the down‐regulated
genes at both 16 and 36 h (Fig 3B; Supporting Information
Fig S3A). The reduction of a subset (n ¼ 10) of the differentially
expressed MYC‐target genes was validated by qRT‐PCR in
FBXO28 depleted HCT116 and U2OS cells (Fig 3C and D;
Supporting Information Fig S3B). In contrast, two control genes
lacking MYC‐speciﬁc E‐boxes or association of MYC in their
promoters according to publically available data (http://genome.
ucsc.edu/ENCODE/analyses) did not exhibit reduced expression
in response to FBXO28 depletion (Fig 3C and D). To address
whether loss of proliferation in response to FBXO28 depletion
depends on MYC, we silenced FBXO28 and MYC separately, or
together in HCT116 cells. As shown in Fig 3E, MYC depletion
reduced EdU incorporation somewhat stronger than FBXO28
knockdown. However, co‐depletion of FBXO28 and MYC did not
further reduce proliferation, suggesting that MYC and FBXO28
act in the same pathway. A similar interdependency was
demonstrated when FBXO28 was depleted in MYC wild‐type
versus MYC‐null rat cells (Supporting Information Fig S3C). In
conclusion, knockdown of FBXO28 has profound effects on
transcriptional processes regulated by MYC, including MYC
target genes regulating macromolecular synthesis, metabolism
and cell proliferation.bles an SCF ubiquitin ligase complex.
pper panel) and pS344-FBXO28 (lower panel) antibodies. Nuclei were
ake-off, re-plated and harvested at the depicted time-points. Protein extracts
icated antibodies. The presence of cells in the G2/M-, G1- and S-phases of the
onous cells.
e assays using recombinant GST-Cyclin/CDK complexes as depicted. IB analysis
S cells was included as a control.
pression constructs, or untagged CDK2 construct, were analysed by IB analysis
ated for 4 h with the CDK inhibitor Roscovitine, with or without MG-132, were
s FBXO28 protein levels were detected using FBXO28 antibodies. Lower panel:
dies on a separate filter. Actin was used as input control.
and S344E) in Cos7 cells. Chased cells were treated for 4 h with MG-132 (MG),
ression constructs encoding Cul1 and Skp1 together with GST-tagged WT-
oteins were eluted and detected by IB using the indicated antibodies.
013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1071
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ubiquitylation but not degradation of MYC
We next investigated whether FBXO28 interacts with MYC. As
shown in Fig 4A and Supporting Information Fig S4A, MYC
efﬁciently coprecipitated with FBXO28, and as expected also
with SKP2 (FBXL1) (Kim et al, 2003; von der Lehr et al, 2003),
but not with the other tested F‐box proteins, including FBXO22,
another of the top‐ranked F‐box genes from the siRNA screen
presented in Fig 1A. Reciprocal coimmunoprecipitation of MYC
veriﬁed the interaction with both WT‐ and DF‐FBXO28 (Fig 4B),
as expected since the F‐box is usually not part of the substrate‐
recognition motif of F‐box proteins (Carrano et al, 1999; Hart
et al, 1999; Strohmaier et al, 2001). Mapping studies showed that
deletion of the highly conserved MYC Box II (MBII) region, but
not the MBI region, clearly reduced the interaction with FBXO28
(Fig 4C; Supporting Information Fig S4B). In contrast, deletion of
the helix–loop–helix leucine zipper (HLH‐LZ) motif in MYC did
not affect binding, while deletion of a larger region of the C‐
terminus (D294–439) including the basic DNA binding region,
MYC box IV and the NLS resulted in reduced afﬁnity (Fig 4C;
Supporting Information Fig S4B). We concluded that the MBII
region and possibly motifs upstream of the HLH‐LZ domain of
MYC are important for the interaction with FBXO28. Finally, the
nuclear interaction between total as well as phosphorylated
endogenous FBXO28with endogenousMYC protein was veriﬁed
by in situ proximity ligation assay (isPLA) (Soderberg et al, 2006)
(Fig 4D; Supporting Information Fig S4C).
Given these ﬁndings, we next investigated whether SCFFBXO28
ubiquitylates MYC. Ubiquitylation assays were performed in
HCT116 FBXW7/ cells to avoid ubiquitylation of MYC by
FBXW7, which is a major ubiquitin ligase for this protein
(Welcker et al, 2004; Yada et al, 2004). As shown in Fig 4E,
expression of WT‐FBXO28 indeed promoted formation of high‐
molecular‐weight MYC‐ubiquitin conjugates in cells, whereas
expression of DF‐FBXO28 abolished MYC poly‐ubiquitylation,
consistent with dominant negative properties of F‐box‐deleted
alleles (DF) (Strohmaier et al, 2001) that can bind substrates but
not the SCF core (Fig 2G). Supporting these results, depletion of
FBXO28 by siRNA heavily impaired MYC poly‐ubiquitylationFigure 3. FBXO28 regulates expression of MYC target genes.
A. Analysis of microarray experiment documenting significantly enriched GO cat
(1200/1690) of the genes were downregulated at 36 h. Selected significantly
expected occurrences are shown as white bars. p-values (shown above black ba
exact test.
B. GSEA analysis of the effects of FBXO28 knockdown on MYC target gene expressi
significantly downregulated in response to FBXO28 depletion. The enrichment s
is overrepresented of the entire ranked list. Each solid bar at the x-axis represen
on the x-axis reflects the change in expression after 16 h FBXO28 depletion.
C. qRT-PCR analysis documenting expression changes of selectedMYC target gene
and
D. in U2OS cells transfected with scrambled or FBXO28 siRNA oligos. Expression va
three independent experiments and bars are SEM. p-values (shown above bars
gene.
E. (Left) Flow cytometry experiments showing the percentage of EdU incorporation
for 48 h. (Right) Silencing efficiency for the siRNAs determined byWB usingMYC
means of three independent experiments and error bars represent SEM. The
compared to siScramble control for each condition.
EMBO Mol Med (2013) 5, 1067–1086  2(Fig 4F). Finally, we found that FBXO28 stimulates poly‐
ubiquitylation of MYC in vitro using recombinant E1, E2,
HA‐ubiquitin and FBXO28 puriﬁed from cells (Supporting
Information Fig S4D).
Since FBXO28 is a CDK1/2 substrate (Fig 2C), we hypothe-
sized that phosphorylation of FBXO28 at S344 might inﬂuence
SCFFBXO28 activity towards MYC. We thus performed in vitro
ubiquitylation assays using immunopuriﬁed wild‐type
(SCFWT‐FBXO28) or mutant (SCFS344A‐FBXO28 and SCFS344E‐FBXO28)
SCF complexes. Strikingly, both the WT (SCF
WT‐FBXO28
) and
phospho‐mimetic (SCFS344E‐FBXO28) SCF complexes stimulated
ubiquitylation of MYC in vitro and in vivo (Fig 4E, G and H),
compared to the phospho‐deﬁcient SCFS344A‐FBXO28 complex
which was much less efﬁcient in catalysing MYC ubiquitylation
(Fig 4G). The reason for the differential ubiquitylation activity of
thesemutants was not due to impaired SCF assembly (Fig 4G and
unpublished data). Consistent with these results, in vivo
ubiquitylation assays demonstrated signiﬁcant inhibitory effects
by DF‐FBXO28 on MYC ubiquitylation in S‐phase, whereas only
a minor inhibitory effect was observed in a population of cells in
G1 phase (Supporting Information Fig S4E). Together, the data
suggest that the intrinsic ubiquitin ligase activity of SCFFBXO28 is
switched on by CDK1/2‐mediated phosphorylation of FBXO28 at
S344, thereby directing ubiquitylation of MYC as cells progress
through S phase.
To investigate whether the interaction between FBXO28 and
MYC was regulated during the cell cycle, we compared the
binding of MYC to DF‐FBXO28 (which is stable also in its non‐
phosphorylated state) expressed in either unsynchronized or
synchronized cells. Although binding was detected in all cell
cycle phases, a slightly reduced interaction was observed in the
G1 and early S phases (Supporting Information Fig S4F).
However, coimmunoprecipitation experiments using the phos-
pho‐deﬁcient S344A mutant showed that phosphorylation at
S344 was not required for FBXO28 to interact with MYC
(Supporting Information Fig S4G), suggesting that the MYC‐
FBXO28 interaction is regulated through an S344‐independent
mechanism, possibly involving phosphorylation or other
modiﬁcations at additional sites. Thus, the reduced ubiquitinegories associated with knockdown of FBXO28 (36 h) in HCT116 cells. 71%
enriched GO categories are represented by black bars and the number of
rs) were adjusted for multiple hypothesis testing and calculated using Fisher’s
on in the microarray data set described in (A) shows that MYC target genes are
core (y-axis) reflects the degree to which the gene set ‘MYCUP PNAS VIA DAVID’
ts one gene within the MYC target gene set and its corresponding distribution
Genes analysed ¼ 80; p < 0.001 (permutation-based).
s (n ¼ 10), and two selected non-MYC target genes as controls, in HCT116 cells
lues are relative to b-ACTIN gene expression. Columns represent the means of
) were calculated using that Student’s t-test compared to siScramble for each
in HCT116 cells upon siRNA knockdown of FBXO28 or MYC alone, or together,
and FBXO28 antibodies, and Actin as loading control. The graphs in (C–E) show
p-values depicted above the bars were determined by the Student’s t test
013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1073
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Diana Cepeda et al.conjugation activity of the SCFS344A‐FBXO28 complex (Fig 4G) is
likely not due to insufﬁcient binding to MYC. Instead, CDK‐
mediated phosphorylation of FBXO28 at S344 appears to be
critical for SCFFBXO28 ubiquitin conjugation activity and poly‐
ubiquitylation of MYC.
To test whether ubiquitylation of MYC by FBXO28 stimulates
its degradation, wemeasured the steady‐state levels and stability
of MYC protein by CHX chase and immunoblot analysis. As
shown in Fig 4I and Supporting Information Fig S4H, expression
of either WT‐ or DF‐FBXO28, did not signiﬁcantly affect MYC
protein levels or stability in HCT116 cells. In addition, depletion
of FBXO28 by siRNA did not change the half‐life of endogenous
MYC protein (Fig 4J and Supporting Information Fig S4H).
Similar results were found in HCT116 FBXW7/ cells
indicating that FBXO28 does not inﬂuence MYC turnover
(Supporting Information Fig S4I and J). Taken together, we
conclude that SCFFBXO28 is a bona ﬁde ubiquitin ligase promoting
MYC poly‐ubiquitylation in response to CDK‐mediated S344
phosphorylation without inducing proteolytic degradation
of MYC.
SCFFBXO28 ubiquitin ligase activity promotes MYC‐driven
transcription by stimulating MYC‐p300 interactions at target
promoters
To assess whether SCFFBXO28 ligase activity is required for MYC‐
induced transcription, we ﬁrst performed transient promoter/
luciferase reporter assays using a construct containing a minimal
promoter with multiple MYC binding sites. As shown in Fig 5A,
overexpression of the dominant‐negative DF‐FBXO28 mutant or
siRNA‐mediated FBXO28 depletion in HeLa cells attenuated
MYC‐induced luciferase reporter activity. In contrast, the salt‐
induced kinase (SIK) gene promoter/luciferase reporter, which
does not contain MYC binding sites, and a minimal promoter/
reporter containing four SMAD‐binding sites did not respond to
either MYC or DF‐FBXO28 overexpression nor to FBXO28Figure 4. FBXO28 phosphorylation promotes MYC ubiquitylation but not deg
A. Extracts fromHEK293 cells cotransfected with the indicated expression constru
Whole cell extracts were IB with Flag antibodies as input control. Blots were
(unpublished data), with black lines delineating the boundaries between non
B. Extracts from HEK293 cells cotransfected with the indicated expression constr
C. Schematic diagram depicting the differentMYC deletion constructs used tomap
the ability of each MYC mutant to interact with FBXO28. MBI/II, MYC Box I an
D. In situ proximity ligation assay (isPLA) to examine endogenous interactions bet
from top, MYC þ FBXO28 antibodies, MYC þ MAX antibodies, MYC þ pS344-
E. In vivo ubiquitylation assay in HCT116 FBXW7/ cells cotransfected with the
harvesting followed by IP with MYC antibodies (N262). Ubiquitylation of endoge
whole cell extracts with the indicated antibodies is shown.
F. Ubiquitylation of exogenous MYC was analysed as in (E) in HCT116 FBXW7/
G. The indicated SCFFBXO28 complexes were used in an in vitro ubiquitylation re
Ubiquitin and an energy regenerating system. MYC protein ubiquitylation wa
associated SCF complexes was assessed by Cul1 and Roc1 IB analysis, respec
H. In vivo ubiquitylation assay in U2OS cells expressing doxycycline-inducible S34
treated with MG-132 4 h prior to harvesting, followed by IP using MYC antib
analysis with MYC (C33) antibody. IB analysis of whole cell extracts with the
I. HCT116 cells were transfected with the indicated expression constructs and MY
prepared at each time point following addition of CHX and MYC protein leve
J. MYC protein turnover in HCT116 cells transfected with the indicated siRNAs was
experiments.
EMBO Mol Med (2013) 5, 1067–1086  2depletion, further supporting the preferential requirement of
FBXO28 for speciﬁc transactivation of MYC target genes
(Supporting inforation Fig S5A and B). Furthermore, doxycy-
cline (Dox)‐induced expression of DF‐FBXO28 in asynchronous-
ly proliferating U2OS cells signiﬁcantly reduced the expression of
several endogenous MYC target genes (Fig 5B).
Considering that phosphorylation of FBXO28 at S344 occurs
during progression through the S and G2/M phases of the cell
cycle (Fig 2B) and is required for ubiquitylation of MYC (Fig 4G
and H), we next analysed expression of MYC target genes upon
expression ofWT‐FBXO28 andDF‐FBXO28 in S‐phase cells. Dox‐
regulated U2OS cells were synchronized at the G1/S border by
double thymidine treatment followed by release into S‐phase. As
shown in Fig 5C and D, WT‐FBXO28 enhanced expression of
several endogenous MYC target genes and DF‐FBXO28 clearly
attenuated transactivation of those genes, compared to control
cells. Similar results were observed in a synchronized population
of HeLa cells released into S‐phase following depletion of
FBXO28 using siRNA (Supporting Information Fig S5C).
To exclude that FBXO28 depletion affected cell cycle genes in
general, we cross‐referenced our microarray data from siFBXO28
treated cells (Fig 3 and Supportive Information Fig S3) with
publically available, cell‐cycle‐speciﬁc, gene expression and ChIP
data (Whitﬁeld et al, 2002) and http://genome.ucsc.edu/
ENCODE/analyses). MYC was found to bind around 3/4 of
the deﬁned cell cycle‐regulated genes (Supportive Information
Fig S5D). Depletion of FBXO28 signiﬁcantly downregulated a
subpopulation of theMYC target genes (in particular in S, G2 and
M‐phases), while non‐MYC target genes seemed less affected (2
non‐MYC versus 33 MYC target genes, p ¼ 0.03). This
demonstrates that FBXO28 knockdown preferentially affects
MYC target genes and does not lead to a general downregulation
of gene expression in S‐G2 phases of the cell cycle.
We next addressed whether FBXO28 plays a more direct role
in MYC‐mediated transcription and associates withMYC bindingradation of MYC.
cts were IPwithMYC antibodies (N262) and IB with Flag antibody as indicated.
cropped vertically to exclude F-box proteins that are currently under study
-adjacent lanes.
ucts were IP using Flag antibody and IB with MYC antibody (N262) as shown.
the interaction with FBXO28 in Cos7 cells. The symbols to the right summarize
d II; b, basic region; HLH, Helix–loop–helix region; LZ, Leucine Zipper region.
ween FBXO28 and MYC in HeLa cells. Top panel, negative control; next panels
FBXO28 antibodies, respectively. Scale bars, 20 mm.
indicated expression constructs and treated with MG-132 for 4 h prior to
nous MYC protein was detected by IB analysis with HA antibody. IB analysis of
 cells transfected with the indicated siRNAs and expression constructs.
action with FLAG-MYC in the presence of recombinant E1, E2 (UbcH5), HA-
s detected by IB analysis using anti-HA antibody. Formation of FBXO28-
tively. S/E: S344E-FBXO28, S/A: S344A-FBXO28.
4E-FBXO28 (S/E) and DF-FBXO28 (DF) constructs, transfected with HA-Ub and
odies (N262). Ubiquitylation of endogenous MYC protein was detected by IB
indicated antibodies is shown.
C protein turnover was analysed by CHX-chase assay. Whole cell extracts were
ls detected by IB.
analysed as in (I). b-Actin levels were used as a general loading control inmost
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Diana Cepeda et al.sequences in MYC target genes. As depicted in Fig 5E,
quantitative chromatin IP (Q‐ChIP) assays using U‐937 cells
demonstrated that FBXO28 (and phosphorylated FBXO28) was
speciﬁcally enriched within the E‐box regions of the ODC1,
CYCLIN D2 (CCND2) and rDNA gene promoters, to which MYC
binds together with its obligatory partner MAX, but not at the
FAS ligand gene promoter, which lacks E‐box motifs. Signiﬁcant
enrichment of FBXO28 at these promoters as well as additional
MYC targets, including the PTMA, BMI1 and RFC4 gene
promoters, was also detected in U2OS and HCT116 cells
(Supporting Information Fig S5E and F). As would be expected
for a cofactor that binds DNA indirectly through transient
interactions with DNA‐binding transcription factors, FBXO28
enrichment at target promoters was generally weaker as
compared to MYC (or MAX, Fig 5E; Supporting Information
Fig S5E and F and unpublished data).
Since the MYC/MAX transcriptional complex regulates
transcription, at least in part, by inﬂuencing the local chromatin
structure at promoters (Adhikary & Eilers, 2005; Eilers &
Eisenman, 2008; Larsson & Henriksson, 2010; Meyer &
Penn, 2008), which is important both for initiation and
elongation of transcription, we reasoned that ubiquitylation of
MYC by SCFFBXO28 might be required to support speciﬁc MYC‐
coactivator interactions of relevance for chromatin regulation,
such as the histone acetyltransferase (HAT) p300 which has
previously been shown to interact with MYC (Adhikary
et al, 2005; Faiola et al, 2005; Vervoorts et al, 2003). Indeed,
the enrichment of HAT p300 and of acetylated histone H4 at the
CCND2 and BMI1 gene promoters was severely impaired upon
expression of DF‐FBXO28 in U2OS cells (Fig 5F and G;
Supporting Information Fig S5G and H), while MYC and MAX
binding was not affected (Supporting Information Fig S5I).In
contrast, neither association of p300 nor histone H4 acetylation
was affected by expression of DF‐FBXO28 at the CA‐1 promoter,
which is not bound by MYC (Fig 5H and I). These data are
consistent with a role of SCFFBXO28 ubiquitin ligase activity in
recruitment of p300 to MYC at target gene promoters, but not toFigure 5. SCFFBXO28 ubiquitin ligase activity promotes MYC‐driven transcripti
A. Promoter/luciferase reporter assay in HeLa cells transfected with the M4mi
Luciferase activity was normalized to b-Galactosidase control. The data is repr
measurements.
B. qRT-PCR analysis documenting the expression levels of MYC target genes upo
U2OS cells. The graphs depict means of three independent experiments; bars
bars (Student’s t-test).
C. qRT-PCR expression analysis of the indicated MYC target genes in U2OS cells
double thymidine treatment. WT-FBXO28 expression was induced by doxycycl
data represent the average of two independent experiments
D. qRT-PCR of selected MYC target genes in U2OS cells expressing doxycycline
E. Q-ChIP assay in U-937 cells with the indicated antibodies at the depicted gen
Enrichment was quantified by q-PCR, normalized to input DNA and presente
representative of two or three independent experiments.
F–I. Q-ChIP assays measuring the associating of p300 (F and H) or acetylated hi
carbonic anhydrase I (CA1) non-MYC target gene promoter (H and I), upon do
SEM of the average of two independent experiments, normalized to % inpu
J. Analysis of interaction between MYC-MAX (upper panel) and MYC-p300 (mid
U2OS cells transfected with a MYC expression plasmid. Cells were treated wi
analysis with the indicated antibodies. Ten percent of each lysate was used
EMBO Mol Med (2013) 5, 1067–1086  2promoters in general. To test this hypothesis, we assessed p300‐
MYC complex formation by coimmunoprecipitation analysis in
cells expressing WT‐FBXO28 or DF‐FBXO28. As shown in Fig 5J,
neither WT‐FBXO28 nor DF‐FBXO28 affected the binding of
MYC to MAX. However, DF‐FBXO28 expression abrogated the
interaction betweenMYC and p300, as compared toWT‐FBXO28
expression (Fig 5J).
To investigate what lysines in MYC are targeted for
ubiquitylation by FBXO28 and possibly of importance for
regulating the MYC‐p300 interaction, we examined ubiquityla-
tion of speciﬁc C‐terminal MYC deletion constructs upon
expression of DF‐FBXO28. We found that while DF‐FBXO28
expression reduced ubiquitylation of WT‐MYC and a C‐terminal
MYC deletion mutant (D367–439), it did not signiﬁcantly affect
the ubiquitylation status of MYC truncations lacking amino acids
294–439 (Supporting Information Fig S5J). Since ubiquitylation
on one or more of six lysine residues within this region was
previously reported to promote ubiquitin‐mediated complex
formation between MYC and p300 (Adhikary et al, 2005), we
next tested if these particular lysines (K6R) are potential targets
for the SCFFBXO28 ubiquitin ligase. Indeed, we found that while
expression of DF‐FBXO28 reduced ubiquitylation of full‐length
MYC and a MYC mutant where lysines at positions 51 and 52
(NK2R) had been replaced with arginines, it did not attenuate
ubiquitylation of the K6R mutant (Supporting Information Fig
S5K). Thus, SCFFBXO28 promotes ubiquitylation on speciﬁc lysine
residues within the 294–367 region of MYC, which is known to
be involved in ubiquitin‐mediated MYC‐p300 interaction.
Therefore, these data indicate that SCFFBXO28‐mediated MYC
ubiquitylation promotes MYC‐driven transcription by facilitating
recruitment of p300 and possibly other cofactors to target
promoters.
SCFFBXO28 activity promotes MYC‐induced tumourigenesis
To explore the physiological importance of SCFFBXO28 E3 ligase
activity, we measured the effect of DF‐FBXO28 on tumour cell
proliferation and MYC‐induced tumourigenesis. As expected,on by stimulating MYC‐p300 interactions at target promoters.
ntk-Luc reporter in combination with the indicated expression constructs.
esentative of three experiments and bars represent the mean  SEM for three
n doxycycline-induced DF-FBXO28 expression in asynchronously proliferating
represent SEM, with p-values compared to EV for each gene shown above the
released into S-phase (4 h) following synchronization at the G1/S border by
ine treatment prior to synchronization. Values were normalized to b-ACTIN and
-inducible DF-FBXO28. Experiments and analyses were performed as in (C).
e promoters. GFP antibody was used as a negative control in all experiments.
d as the average of three determinations. Error bars represent SEM. Data is
stone H4 (G and I) at the CCND2 MYC target gene promoter (F and G) or the
xycycline-induced DF-FBXO28 expression in U2OS cells. Error bars represent
t.
dle panel) upon doxycycline-induced expression of EV, WT- or DF-FBXO28 in
th doxycycline for 24 h and lysates were subjected to coimmunoprecipitation
as input controls (lower panel).
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Figure 6. SCFFBXO28 Activity promotes MYC‐Induced Tumourigenesis.
A. Cell proliferation analysis documenting loss of proliferation upon expression of DF-FBXO28 as compared to EV in U2OS cells. Cells were treated with
doxycycline for 48 h, counted and replated at equal numbers in the presence of doxycycline, as indicated. The data represent the average  SEM of three cell
counts for each time point.
B. Colony formation assays documenting the effect of overexpression of DF-FBXO28 in U2OS cells. Equal numbers of cells were transfected with the indicated
expression constructs, plated in triplicates and selected with G418 for 10 days. Colonies were fixed and stained with Giemsa.
C. Soft agar colony formation assays using P53/MEFs transduced with the indicated retroviruses. Transformation was scored by counting colonies of relatively
the same size across all conditions. Representative data of the mean from three counts  SEM for one of three independent experiments.
D. Tumour growth in immunodeficient mice injected with MYC-transformed P53/MEFs stably transduced with either EV or DF-FBXO28. Tumour growth was
measured using a caliper at the indicated times after injection as indicated. Right panel: Representative image of tumours. Scale bar, 10 mm. Graph presents
the average tumour size of five mice per group, with two tumours (one on each flank); error bars indicate SEM. p-values between the groups, shown above error
bars, were calculated for each timepoint using one-way ANOVA.
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1078Dox‐induced expression ofDF‐FBXO28 in U2OS cells signiﬁcantly
reduced cell numbers after 2–3 days (Fig 6A) similar to FBXO28
depletion (Fig 1D). Ectopic expression of DF‐FBXO28 also
signiﬁcantly reduced the ability of these cells to grow as colonies
on plastic (Fig 6B). To directly test whether FBXO28 activity is
required for MYC‐induced transformation, we engineered
P53/ immortalized mouse embryonic ﬁbroblasts (MEFs)
(which are known to be efﬁciently transformed by MYC (Ecker
et al, 2009), with retroviruses encoding MYC and DF‐FBXO28, or
the individual genes, and performed transformation assays.
Notably, DF‐FBXO28 expression signiﬁcantly reduced MYC‐
induced foci formation (unpublished data) and colony formation
in soft agar (Fig 6C). A similar reduction inMYC‐induced colonies
was observed when FBXO28 was depleted in MYC‐transduced
P53/ MEFs (Supporting Information Fig S6A). DF‐FBXO28
expression did not signiﬁcantly affect the number of RAS‐induced 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.colonies in these cells (unpublished data), further supporting the
notion that FBXO28 activity is speciﬁcally linked to MYC‐driven
transformation. To determine whether FBXO28 activity is
important for MYC‐driven tumour growth, MYC‐transformed
MEFs were transduced with DF‐FBXO28 retroviruses, and pools
of puromycin‐resistant MEFs expressing DF‐FBXO28 were
subsequently injected into immunodeﬁcient mice. As shown
in Fig 6D, these tumours grew signiﬁcantly slower, as compared
to the control mice injected with MEFs expressing MYC alone.
The ability of the tumours to retain expression ofDF‐FBXO28was
conﬁrmed by immunoblotting (Supporting Information Fig S6B).
Thus, expression of dominant‐negative DF‐FBXO28 was sufﬁ-
cient to suppress MYC‐induced transformation in vitro and
tumour growth in vivo. Together, these data strongly imply that
SCFFBXO28 ubiquitin ligase activity is required to support MYC‐
dependent transcription and tumourigenicity.EMBO Mol Med (2013) 5, 1067–1086
Figure 7. High Expression of FBXO28 in human breast cancer correlates with MYC pathway activity.
A. Box plot analysis of FBXO28 expression levels across a variety of cancer tissues. The box refers to the quartile distribution (25–75%) range, with the median
shown as a black horizontal line. In addition, the 95% range and individual outlier samples are shown.
B. High expression of FBXO28 in human breast cancer. Summary of 31 different microarray-based breast cancer studies retrieved from the Oncomine database
(OncomineTM, Compendia Bioscience, Ann Arbor, MI, https://www.oncomine.org/) is shown. Studies include tumour tissue versus normal tissue, high grade
versus low-grade tumour, as well as recurrence and survival rates (numbered and referenced in Table S2 of Supporting Information). The diagram displays the
percentile rank for FBXO28 across each of the analyses by the degree of colour saturation of the box. Themost highly saturated boxes denote that the gene rank
is in the top 1 percentile for that analysis; medium saturation in the top 5 percentile, and pale in the top 10 percentile. Red denotes over-expression. The
differential expression p-value for the median-ranked analysis was calculated using an independent, two-sample, one-tailed Welch’s t-test (https://www.
oncomine.org/).
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with activation of a gene subset targeted by the MYC/p300
pathway
The strong association between FBXO28, MYC and tumouri-
genesis in the above model systems prompted us to further
evaluate if this relationship is important also in the context of
primary human tumour cells. Analyses of FBXO28 mRNA
expression in various malignant tissues using the in silico
transcriptomics database of the GeneSapiens System (www.
genesapiens.org) demonstrated elevated levels in several
different tumour types, including breast cancer, gynecological
tumours, sarcomas and neuronal tumours (Fig 7A). Indeed,
searching the Oncomine database (Rhodes et al, 2004) veriﬁed
that FBXO28 expression was signiﬁcantly higher in primary
breast cancers relative to normal breast tissue in multiple
expression proﬁling studies (Fig 7B and Supporting Information
Table S2). To directly evaluate the potential association
between FBXO28 expression and the expression of MYC target
genes in breast cancer, we extracted gene expression data
representing 327 clinical breast cancer specimens ((Loi
et al, 2007); GSE6532) and identiﬁed 102 genes highly relatedEMBO Mol Med (2013) 5, 1067–1086  2to FBXO28 expression. Of these genes, 35 were positively
correlated and 67 were negatively correlated to FBXO28
expression (Supporting information Tables S3 and S4). Detailed
analyses of the gene expression network using publically‐
available ChIP‐seq data (http://genome.ucsc.edu/ENCODE/
analyses) revealed that there was a highly signiﬁcant overrep-
resentation (p ¼ 3.8E15) of MYC binding at the promoter
regions among the positively correlated genes (29 of the 35
positively correlated genes), in relation to the negatively
correlated genes (6 of the 67 genes) (Supporting Information
Tables S3 and S4). Finally, using available p300 ChIP‐seq data
we also found a strong trend (p ¼ 0.055) towards coassociation
of p300 with MYC at overlapping peaks at the promoters of
positively correlated genes (66%), whereas MYC was less
frequently associated with p300 at negatively correlated genes
(25%) (Supporting Information Tables S3 and S4), in line with
the presented molecular data (Fig 5; Supporting Information Fig
S5). We conclude that FBXO28 expression is positively
correlated with increased expression of a subset of genes that
are preferentially targeted by MYC in association with p300 in
human breast cancer.013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1079
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1080Expression and phosphorylation of FBXO28 is associated
with poor prognosis and worse survival in human breast
cancer
In light of the ﬁndings described above, we further explored the
potential involvement of FBXO28 in breast tumourigenesis.
FBXO28 immunoblot analysis in a cohort of primary breast
tumour specimens (cohort 1, n ¼ 72), demonstrated a statisti-
cally signiﬁcant correlation between high FBXO28 protein levelsFigure 8.
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.and poorly differentiated breast tumours (p ¼ 0.039) (Fig 8A).
We also observed substantial variation in the levels of
phosphorylated FBXO28 in these breast tumours (Supporting
Information Fig S7A). We next evaluated FBXO28 phosphoryla-
tion by immunohistochemistry (IHC) analysis performed on
tissuemicroarrays (TMAs) the pS344‐FBXO28 speciﬁc antibody in
a second and independent cohort of 144 breast tumour specimens
(cohort 2). Strikingly, a statistically signiﬁcant correlation wasEMBO Mol Med (2013) 5, 1067–1086
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Diana Cepeda et al.found between a high nuclear fraction (NF) of pS344‐FBXO28 and
several adverse clinicopathological characteristics, including
tumour size, poorly differentiated and ER‐negative tumours
(Supporting Information Table S5A). This suggests that expres-
sion and phosphorylation of FBXO28 may be linked to clinical
outcome in breast cancer. Indeed, the NF of phosphorylated
FBXO28 clearly separated breast tumours according to OS, as
evaluated by log‐rank analysis of Kaplan–Meier curves (Fig 8B).
When the FBXO28 datawere dichotomized intoNF < 25% versus
NF > 25%, a signiﬁcant association between high NF of pS344‐
FBXO28 and OS (p ¼ 0.003), breast cancer‐speciﬁc survival
(BCSS) (p ¼ 0.011) and recurrence free survival (RFS) (p
¼ 0.016) was demonstrated (Fig 8C; Supporting Information
Fig S7B). Using Cox modeling, we found a strong association
between a high NF of FBXO28 and decreased OS (p ¼ 0.005),
BCSS (p ¼ 0.020) and RFS (p ¼ 0.024) (Supporting Information
Table S5B). Importantly, when analysed by multivariate analysis,
the NF of FBXO28 retained its prognostic signiﬁcance as an
independent predictor of poor OS in breast cancer (HR 3.19 [1.22–
8.33], p ¼ 0.018) (Supporting Information Table S5C).
To validate and extend these results, we performed TMA
analysis of FBXO28 expression and phosphorylation in an
additional large and independent breast cancer cohort (cohort 3,
n ¼ 498). In this cohort, a high NF of phosphorylated FBXO28
was also associated with aggressive disease (Supporting
Information Table S6A), worse OS (Fig 8D), BCSS and RFS
(Supporting Information Fig S7C). In addition, when total
FBXO28 protein expression levels were evaluated according to
nuclear staining intensity (NI), Kaplan–Meier analysis showed
that increased levels of FBXO28 protein were associated with
decreased OS (Fig 8D), BCSS and RFS (Supporting Information
Fig S7D). Importantly, both FBXO28 expression (NI) and
phosphorylation (NF) were found to be independent predictors
of worse outcome by multivariate analysis also in this cohort of
breast cancer patients (Supporting Information Table S6B and
C). Remarkably, we found that FBXO28 phosphorylation was
associated with worse survival also in speciﬁc patient subgroupsFigure 8. Expression and phosphorylation of FBXO28 are associated with poo
A. Left panel: IB analysis of FBXO28 protein expression in a subset of primary brea
FBXO28 protein levels and its relationship with tumour grade was calculated aft
of patients with high FBXO28 levels and grey bars denote the percentage of p
NHGIII). p ¼ 0.039 calculated using one-tailed Fisher’s exact test. (n ¼ 72, co
B. Kaplan–Meier plot of OS in breast cancer patients (n ¼ 144, cohort 2) stratified
in the nucleus. A log rank test was used to show differences between patient gr
was performed using anti-S344-FBXO28 antibody.
C. Left panel: A log rank test was used to show differences between patient grou
(cohort 2) (p ¼ 0.003). Right panel: Representative images of breast carcinoma T
in (B).
D. Kaplan–Meier plots of OS in breast cancer patients (n ¼ 498, cohort 3) stratified
(left panel, p ¼ 0.003) or the nuclear staining intensity (NI; 1 ¼ low, 2 ¼ mo
Immunohistochemistry analysis was performed using the anti-pS344-FBXO28
E. Kaplan–Meier plots of OS in breast cancer patients (n ¼ 498, cohort 3) classifi
p ¼ 0.030) tumours. Patients were stratified according to the NF of FBXO28 ph
using 25% NF as a cut-off. NHGIII, Nottingham histological grade III.
F. FBXO28 is phosphorylated by CDK1/2 during progression through the S- and G
SCFFBXO28, promoting non-proteolytic ubiquitylation of MYC, interaction with
resulting in increased transcription, proliferation, transformation and tumour
EMBO Mol Med (2013) 5, 1067–1086  2with particularly adverse prognosis, including the most highly
proliferative (measured by Ki‐67 analysis) and poorly differenti-
ated (high‐grade) tumours (Fig 8E) and interestingly, also in
Luminal A tumours, which are generally characterized by a
uniformly low proliferation status (Supporting Information Fig
S7E). Notably, these data indicate that expression and
phosphorylation of FBXO28 do not simply reﬂect the prolifer-
ative status of the tumours; however, we cannot exclude the
possibility that FBXO28 might regulate other aspects of poor
outcome (such as invasion), irrespective of its association with
high CDK activity and poor prognosis. Nevertheless, these data
underscore the clinical relevance and prognostic impact of
FBXO28 in human breast cancer.DISCUSSION
In this study, we provide the ﬁrst clues as to the function of the
F‐box protein, FBXO28. Initially, FBXO28 was identiﬁed in a
high‐throughput, unbiased loss‐of‐function screen for genes
required for efﬁcient tumour cell proliferation (Fig 1). In line
with its role as a regulator of tumour cell proliferation, we
discovered that cells depleted of FBXO28 downregulated genes
activated by the transcription factor MYC (Fig 3). This work
further establishes that FBXO28 is a bona ﬁde ubiquitin ligase for
MYC and also demonstrates a novel posttranslational regulatory
network in which CDK‐mediated phosphorylation of FBXO28
promotes non‐proteolytic MYC ubiquitylation (Fig 4) and
recruitment of the cofactor p300 to MYC target gene promoters
(Fig 5). The function of FBXO28 in regulation of MYC activity is
also supported by the ﬁndings that depletion or functional
inactivation of FBXO28 attenuates MYC‐induced transformation
in vitro and MYC‐driven tumour growth in vivo (Fig 6). In line
with the molecular data, we found an association between
FBXO28 expression and the expression of MYC target genes in
human breast cancer (Table S3) and importantly, that elevated
levels of FBXO28 protein expression and phosphorylation arer outcome in human breast cancer.
st tumour specimens from cohort 1. Right panel: Semi-quantitative analysis of
er normalization against an input control. Black bars represent the percentage
atients with low FBXO28 levels, in each respective patient group (NHGI/II vs.
hort 1).
according to the fraction of cells staining positive for phosphorylated FBXO28
oups with different nuclear fractions (NF) (p ¼ 0.023). Immunohistochemistry
ps with high (>25%) and low (<25%) NF of phosphorylated FBXO28 and OS
MA cores with a low (<25%) and a high (>25%) NF. Analysis was performed as
according to the nuclear fraction (NF; 25% cut-off) of phosphorylated FBXO28
derate, 3 high) of FBXO28 protein (right panel, p ¼ 0.014).
, and the FBXO28 antibody detecting total FBXO28 protein.
ed as high-grade (NHGIII) (left panel, p ¼ 0.013), and high-Ki67 (right panel,
osphorylation. A log-rank test was used to show differences between groups
2-phases of the cell cycle. Phosphorylation of FBXO28 at serine 344 activates
the transcriptional cofactor p300 and transcription of MYC target genes
igenesis.
013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1081
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1082strong and independent predictors of poor outcome in breast
cancer (Fig 8).
To date, apart from FBXO28, at least ﬁve E3 ubiquitin ligases,
SKP2, FBXW7, HECTH9/HUWE1, TRUSS and bTRCP have been
shown to regulate MYC (Adhikary et al, 2005; Choi et al, 2010;
Kim et al, 2003; Popov et al, 2010; Thomas & Tansey, 2011; von
der Lehr et al, 2003; Welcker et al, 2004; Yada et al, 2004; Zhao
et al, 2008). The reason for this apparent redundancy is not fully
understood, but a likely cause is that powerful oncoproteins like
MYC need to be maintained under rigorous control, and it is
conceivable that different ligases regulate MYC activity and/or
degradation in response to various speciﬁc signals. The primary
role of a subset of the aforementioned E3 ligases seems solely to
act as negative (FBXW7 and TRUSS) or positive (bTRCP)
regulators of MYC protein stability by conjugating different types
of poly‐ubiquitin chains (Choi et al, 2010; Popov et al, 2010;
Welcker et al, 2004; Yada et al, 2004). In contrast, FBXO28
belongs to another category of ubiquitin ligases, which also
includes SKP2 and HECTH9/HUWE1, that play a role in
promoting MYC activity (Adhikary et al, 2005; Kim
et al, 2003; Thomas & Tansey, 2011; von der Lehr
et al, 2003), although HECTH9/HUWE1 has also been reported
to stimulate the degradation of MYCN (Zhao et al, 2008). One of
the prominent features of the SCFFBXO28 ubiquitin ligase is that it
needs to be phosphorylated on serine 344 by cyclin A/CDK2 or
cyclin B/CDK1, but not cyclin E/CDK2, in order to exert its
ubiquitin ligase activity towards MYC, demonstrating a particu-
lar need for SCFFBXO28 in coordinating the activity of distinct
CDKs with MYC function during the cell cycle. We suggest a
model where CDK1/2‐mediated phosphorylation of FBXO28
triggers the activation of the SCFFBXO28 ligase and subsequent
ubiquitylation of MYC at the S‐ and G2/M phases of the cell
cycle. This promotes the recruitment of the cofactor p300
thereby stimulating transcriptional activation of a subset of MYC
target genes critical for the continued progression through the
cell cycle (Fig 8F). In comparison, SKP2‐ and HECTH9‐mediated
ubiquitylation of MYC has been reported to play a more
prominent role in the G1 or the G1/S phase transition (Adhikary
et al, 2005; Kim et al, 2003; von der Lehr et al, 2003). FBXO28 and
HECTH9/HUWE1 seem to operate in a similar manner by
targeting speciﬁc lysines in the C‐terminal part of MYC, in the
case of HECTH9 through lysine 63‐linked ubiquitin chains,
which enhance recruitment of p300 to MYC (Adhikary
et al, 2005). Since FBXO28 promotes non‐proteolytic ubiquity-
lation of MYC, the conjugated ubiquitin chains are likely to be
non‐lysine 48‐linked as in the case for HECTH9, or possibly
heterotypic ubiquitin chains as reported for bTRCP (Popov
et al, 2010). It is therefore conceivable that SKP2, HECTH9 and
FBXO28 promote MYC‐driven transcription of overlapping or
distinct subsets of MYC target genes in different phases of the cell
cycle and/or in response to different signals. These are important
issues that need to be addressed in future studies.
Recent ﬁndings suggest that MYC enhances global expression
from E‐box‐containing promoters in an active or poised state
(Lin et al, 2012; Nie et al, 2012). However, it is also clear that
MYC has different effects on different genes, for instance due to
the concentration of E‐boxes, or as a result of enhancer invasion 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.at high enough MYC levels, and collaboration with other
transcription factors or cofactors. Our present ﬁnding of
cooperativity between MYC and FBXO28 exempliﬁes an
additional level of complexity to MYC‐regulated transcription
by demonstrating that cofactors like FBXO28 seem to regulate a
subset of MYC target genes (Fig 3B, Supporting Information Figs
S3A and S5D).
We found that CDK‐mediated phosphorylation at serine 344
stimulates SCFFBXO28 activity towards MYC. This type of
regulation, phosphorylation of the ubiquitin ligase rather than
the substrate, resembles the regulation of the multisubunit E3
ligase APC (anaphase‐promoting complex) by CDKs (Rahal &
Amon, 2008). The regulation of SCF activity is poorly understood,
but mechanism(s) involving dimerization and auto‐ubiquityla-
tion or interaction with speciﬁc cofactors have been proposed
(Cope & Deshaies, 2006). For instance, CDK‐mediated phosphor-
ylation affects SKP2 stability, and allows its expression in mid‐G1
phase by protecting it from degradation (Rodier et al, 2008).
Interestingly, we found that phosphorylation of FBXO28 at S344
inﬂuences its stability, with a reduced turnover rate when
FBXO28 is phosphorylated (Fig 2). Thus, CDKs not only control
SCFFBXO28 activity, but also impact on FBXO28 protein levels and
stability (Fig 2), presumably through a mechanism involving
auto‐ubiquitylation and self‐destruction of FBXO28 at low
S‐phase CDK activity (Supporting Information Fig S2G and H).
Exactly how phosphorylation at S344 affects SCF activity towards
MYC remains to be determined, but S344 phosphorylation does
not appear to be essential for FBXO28 to interact with MYC
(Supporting Information Fig S4G). It is noteworthy that the S344
is positioned in a loop between two predicted helices in the
FBXO28 C‐terminus, potentially inﬂuencing FBXO28 dimeriza-
tion and/or SCF activity through a conformational change
triggered by CDK‐dependent phosphorylation. However, we
cannot exclude that binding between FBXO28 and MYC is
regulated by CDK‐mediated phosphorylation at other sites or by
other modiﬁcations, since somewhat reduced binding of the
stableDF‐FBXO28mutant toMYCwas observed in G1 and early S
phase (Supporting Information Fig S4F).
Intriguingly, CDK1 and CDK2 also target MYC for phosphor-
ylation (Hydbring et al, 2010; Sjostrom et al, 2005), thus
regulating the transcriptional activity of MYC (Hydbring
et al, 2010). Thus, distinct CDK activities may operate and
coordinate FBXO28 and MYC function during the cell cycle, and
the discovery of FBXO28 therefore introduces a mechanistic link
between activation of CDKs and downstream activation of the
MYC pathway. In fact, many of the features of FBXO28, such as
effects on proliferation, and its connection to tumourigenesis,
might be directly linked to the MYC pathway. Our observation
that knockdown of FBXO28 in MYC‐depleted cells does not
result in any further reduction in proliferation supports this
notion. The ﬁndings that FBXO28 depletion or expression of
dominant‐negative FBXO28 (DF‐FBXO28) impairs MYC‐induced
oncogenic transformation and tumour growth indicate that
FBXO28 is a rate‐limiting factor in MYC‐driven tumourigenesis,
although we cannot rule out the possibility that FBXO28
ubiquitylates additional substrates and has MYC‐ and/or CDK‐
independent functions as well.EMBO Mol Med (2013) 5, 1067–1086
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high expression and phosphorylation of FBXO28 positively
correlate with several adverse clinicopathological characteristics
and poor outcome in breast cancer (Figs and 8). Importantly, we
found a strong association between poor overall‐, breast‐cancer
speciﬁc‐ and relapse‐free‐survival and high FBXO28 protein
levels in two independent cohorts, and in multivariate analysis,
expression and phosphorylation of FBXO28 were independent
predictors of poor survival (Supporting Information Tables S5
and S6). Since FBXO28 phosphorylation and overall expression
levels are coupled to CDK activity, it is possible that the
correlation between high FBXO28 levels and poor outcome
partly reﬂects an increased proliferation in the tumours with
high CDK activity. However, high FBXO28 levels were also
found to be associated with poor prognosis in particular patient
subgroups, including low proliferative luminal A tumours and in
highly proliferative (high Ki‐67 levels), poorly differentiated
breast tumours (Fig 8E and Supporting Information Fig S7E),
presumably tumours with hyperactivation of MYC (Xu et al,
2010).
Collectively, our data suggest that the E3 ubiquitin ligase
SCFFBXO28 is a downstream effector of CDK1/2 that activates
MYC’s transcriptional function by non‐proteolytic ubiquityla-
tion. The ﬁndings in this study of a mechanistic link between
MYC activity and FBXO28, and the positive association between
high FBXO28 expression and the expression of MYC target genes
in human breast cancer suggest a potential role for FBXO28 in
MYC‐driven breast cancers and underscores the importance of
FBXO28 as a new potential biomarker and candidate for future
drug development, for instance via CDK inhibition, for the
treatment of breast tumours with overexpression of FBXO28
and/or MYC.MATERIALS AND METHODS
Cell Culture, Transfections and Treatments
Tumour‐derived cell lines were cultured according to the guidelines at
the American Type Culture Collection (ATCC) and Clontech. Tet‐On
U2OS cells for inducible FBXO28 expression were generated by stable
transfection with a pTRE2‐PUR‐myc3‐FBXO28 WT or DF‐box con-
structs and selection with puromycin. FBXO28 expression was induced
by addition of doxycycline for 24 h. Transient plasmid transfections
were performed using TransIT‐LT1 (MIRUS, Madison, WI) or Lipofect-
amine 2000 (Invitrogen, Carlsbad, CA) reagents, according to the
manufacturer’s protocols. siRNA transfections were carried out using
HiPerFect transfection reagent, as recommended by the manufac-
turer’s (Qiagen). For the generation of retroviruses, the Phoenix‐Eco
packaging cell line was transfected with the indicated pBabe‐puro/zeo
expression plasmids using the calcium phosphate method. Viral
supernatants were harvested 48 h after transfection and used for
transduction of p53/ MEFs. For colony assays, cells were ﬁxed with
70% ethanol and stained with crystal violet. Treatment with
doxycycline (5 mg/ml), puromycin (1 mg/ml), cycloheximide
(50 mg/ml), MG‐132 (5–25 mM), thymidine (2 mM) nocodazole
(125 ng/ml), or roscovitine (10 mM) was carried out as indicated.
Chemicals were purchased from Sigma.EMBO Mol Med (2013) 5, 1067–1086  2siRNA functional library screen and proliferation analysis
The proliferative potential of siRNA loss‐of‐function was examined
using the cell spot microarray (CSMA) technology as previously
described (Rantala et al, 2011). Cells were stained with anti‐EdU Alexa
647 and Propidium Iodide dyes according to manufacturer’s
instructions (Invitrogen) and analysed on a FACS LSRII (BD Biosciences).
FACS data analysis was carried out using the CELLQuest software (BD
Biosciences).
Microarray, qRT‐PCR and reporter assays
HCT116 cells were transfected with siRNA oligonucleotides targeting
FBXO28 or a scrambled control sequence for the times indicated. RNA
was extracted using TRIzol reagent (Invitrogen) according to
manufacturer’s instructions. Gene expression analysis was carried
out as previously described (Klevebring et al, 2009) using Operon
microarray slides (Operon Biotechnologies; 34,000 probes). The
analysis was based on equal amount of cells and equal amount of
RNA per cell. Manufacturer‐provided microarray spike‐in hybridization
controls were used at a 1:1 ratio for RNA normalization. For quantitive
real‐time PCR (qRT‐PCR), total RNA was transcribed into cDNA using
random hexamer primers (Fermentas) and SuperScript II Reverse
transcriptase (Invitrogen). qRT‐PCR was performed in triplicates using
SYBR GreenMix (Applied Biosystems) and analysed on an ABI 7300 Real
Time PCR System with SDS software version 1.3.1. PCR primer
sequences are available from authors upon request. TaqMan probes
were used for quantiﬁcation of FBXO28 mRNA (Applied Biosystems).
mRNA expression was calculated according to the DDCt quantiﬁcation
method and the relative expression level of individual genes was
obtained by normalizing the expression to b-ACTIN mRNA expression.
Error bars represent standard deviation of triplicates. Luciferase
reporter assays were performed in HeLa cells transfected with the
mintkM4‐Luc promoter construct containing four E‐boxes. The RSV‐b‐
Galactosidase or Renilla vectors were used for normalization. Luciferase
activities were quantiﬁed in a luminometer (VICTOR3, Perkin–Elmer,
Massachusetts, USA) using the Dual‐Luciferase Reporter Assay System
according to the manufacturer’s protocol (Promega). Fold change was
averaged from at least two separate experiments performed in
triplicates.
Immunoﬂuorescence microscopy and immunoprecipitation
Cells were grown on cover slips and ﬁxed in 4% paraformaldehyde
(PFA), permeabilized with 0.1% Triton X‐100 and incubated with
primary antibodies as indicated. Proteins were detected by staining
using appropriate secondary antibodies. DNA was counterstained with
Hoechst (Sigma) or DAPI. Slides were mounted using Vectashield
(Vector Laboratories), and images were acquired on a Zeiss Axioplan II
imaging microscope equipped with an AxioCam CCD camera (Carl
Zeiss) with Axiovision software (Thornwood, NY).
Cells were lysed on plates in M‐RIPA buffer (50 mM Tris‐HCl pH 8,
250 mM NaCl, 1% Nonidet P‐40, 0.5% deoxycholic acid, 0.05% SDS)
supplemented with Complete protease inhibitor cocktail (Roche) and
Halt Phosphatase inhibitor cocktail (Pierce, Rockford, IL), followed by
brief sonication and centrifugation (10,000  g for 15 min) to clarify
the lysates. Precleared protein extracts (200–500 mg) were incubated
using the indicated antibodies or control IgG antibody at 4°C overnight
and protein complexes were subsequently collected by incubation with
Gammabind G Sepharose beads (GE Healthcare) for 1 h at 4°C. The013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1083
The paper explained
PROBLEM:
Among the approximately 70 F-box genes, which encode
substrate-recognition subunits of SCF ubiquitin ligases, the
biological functions for only a handful have been unraveled so
far. Given the critical function of SCF ubiquitin ligases in
targeting regulatory and cancer-associated proteins for ubiq-
uitylation, a major goal in ubiquitin research is to identify key
oncogenic SCF ubiquitin ligases and their specific target
substrates.
RESULTS:
We identified the F-box protein FBXO28 as part of a SCF complex
that acts as a critical regulator of tumour cell proliferation and
an important modifier of MYC function. SCFFBXO28 ubiquitylates
MYC during the cell cycle after being phosphorylated/activated
by cyclin-dependent kinases (CDKs), but does not destabilize
MYC. Rather, SCFFBXO28 promotes MYC-driven transcription,
proliferation and tumour development, by mediating recruit-
ment of the cofactor p300 to MYC target genes. Finally, high
FBXO28 phosphorylation and expression are very strong and
independent predictors of poor outcome in unrelated cohorts of
breast cancer.
IMPACT:
We identify FBXO28 as a new prognostic factor in breast cancer
and rate-limiting factor in MYC-driven tumourigenesis. Our work
shows that SCFFBXO28 is a downstream effector of CDK1/2 and
suggests that FBXO28 acts as a link between CDKs and activation
of MYC during the cell cycle. Thus, FBXO28 may be a novel
biomarker of poor outcome in breast cancer and a new potential
drug target in MYC-driven tumours.
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1084resin was washed ﬁve times with lysis buffer and associated proteins
eluted by boiling in SDS sample buffer under reducing conditions, after
which proteins were resolved on SDS–PAGE gels and transferred to
PVDF membranes. Proteins were detected by Western blotting
procedures under standard conditions using an enhanced chemilumi-
nescence system (Perkin–Elmer).
Patients and tumour analysis
Breast cancer specimens were obtained from resection of the breast or
lumpectomy at the Department of Obstetrics and Gynecology,
Innsbruck Medical University, Austria and from the Department of
Pathology, Malmö University Hospital, Sweden. All samples were
collected in compliance with and approved by the Institutional Review
Board and with informed consent from the patients. Ethical approvals
were obtained by the relevant Ethics Committees at the Innsbruck
Medical University, Austria and by the Ethics Committee at Lund
University, Sweden. All experiments involving human specimens
conformed to the principles set out in the WMA Declaration of
Helsinki and the NIH Belmont Report.
All animal studies were carried out in accordance with approved
protocols from the Institutional Animal Care and Use Committee. For
additional details on mouse and human tumours, tissue microarray
(TMA) construction, immunohistochemistry (IHC) and image evalua-
tion, see Supporting Information.
Statistical analysis
Chi‐square and Spearman’s rho correlation tests were used for
comparison of phosphorylated FBXO28 in the nucleus and relevant
clinicopathological characteristics. Survival curves were plotted using
the Kaplan–Meier analysis and the log‐rank test was used to illustrate
differences between OS, breast cancer speciﬁc survival (BCSS) and RFS
according to the nuclear fraction (NF) of phosphorylated FBXO28. Cox
proportional univariate and multivariate hazard models were used to
estimate the impact of phosphorylated FBXO28 on OS, BSS and RFS 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.adjusting for patient age, tumour size, ER status, nodal status, HER2
and Nottingham histological grade (NHG). Repeated analyses were
performed on speciﬁc patient subgroups, including luminal A and
high‐grade tumours, separately. All calculations were performed using
the SPSS version 19.0 (SPSS Inc, Chicago, USA) and statistical tests
(Student’s t‐test and Fishers’ exact test) with a p‐value < 0.05 were
considered statistically signiﬁcant.
Additional methods are presented in the Supporting Information.Author contributions
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